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Overweight and obesity are generally defined by body mass index (BMI) criteria, which is useful in large population studies, but flawed in individual patients, since BMI reflects both fat mass and nonfat mass ( mostly muscle and skeletal mass), leading to suggestions that alternative methods to define obesity, including waist circumference (WC) , waist-to-hip-ratio, and percent body fat (% BF) may better reflect at risk body fatness. [1] [2] [3] Obesity is certainly a major risk factor for most cardiovascular (CV) diseases (CVD), including for hypertension (HTN) and coronary heart disease (CHD), two of the major risk factors for the development of heart failure (HF). 1, [4] [5] [6] Additionally, obesity has more direct effects on the pathogenesis of HF, due to its negative impact on cardiac morphology and performance, including negative impact on both systolic and, especially, diastolic left ventricular (LV) function. 5, 6, 7, 8 Therefore,
it is of no surprise that HF is dramatically increased in the setting of obesity.
However, despite the adverse effects that obesity has on CVD risk factors and its association with increased incidence of most CVD, including HTN and CHD, (both of which are strongly related with the increased risk of HF), and for HF itself, many large studies have demonstrated the powerful "obesity paradox" in cohorts with established HF. In fact, the presence of overweight and obese , at least mild obesity in those with HF , appears to confer a better short-and intermediate-term prognosis than in their leaner counterparts who have similar degrees of HF. 5, 6, 9 In this review, we describe the adverse effects of overweight/obesity on hemodynamics, as well as on cardiac structure and ventricular function. The impact of obesity on HF prevalence is reviewed, as well as studies showing an obesity paradox in HF. Finally, we discuss the role of fitness and weight loss in obese patients with HF, as well as the need for more studies on this topic.
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Impact of Obesity on Cardiac Morphology and Performance
Alpert and colleagues 7, 8 have recently reviewed this topic in detail. Considerable evidence underscores the adverse effects of excessive adipose accumulation and associated fat-free mass on central and peripheral hemodynamics, as well as on cardiac structure and systolic and diastolic LV function ( Figure 1 , Table 1 ).
5,7
Hemodynamics. There are many hemodynamic alterations in obesity, leading to increased total and central blood volume and increased stroke volume and cardiac output (CO). 5, 7, 8 Typically, obesity leads to a reduction in systemic vascular resistance in normotensive obese persons, which facilitates the increase in CO despite the fact that heart rate is not substantially impacted in obesity. Arteriovenous oxygen differences are usually widened in obesity, due to lower oxygen extraction by adipose tissue.
Thus, blood flow per unit of weight is reduced, especially in more severe degrees of obesity and in combined obesity/HTN, where systemic vascular resistance is also increased. 5, 7, 8 In Class II and III obesity, increased venous return leads to increased preload with increased LV filling pressure. This further contributes to elevated pulmonary artery and right heart pressures. 5, 7, 8 With exercise in Class III obesity, central blood volume increased by 20%, LV end-diastolic pressure increased by 50%, and the LV dP/dt increased by 57%.
5,10
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7 of obesity. Based on the hemodynamic alterations discussed previously, it seems logical that the elevated blood volume and CO would lead to LV dilatation and more eccentric LVH. However, several studies suggest that in Class I and II obesity, the incidence of concentric remodeling and concentric LVH may exceed the incidence of eccentric LVH. 5.7,8 However, without elevated BP, eccentric LVH may be more prevalent. Obviously, studies that assess the impact of obesity on LV geometry should account for obesity severity and levels of BP, as well as duration of obesity. 5, 7, 8 Ventricular Function. Obesity also has adverse effects on ventricular function. 5, 7, 8, 11, 12 Most studies assessing LV systolic function in obese patients using LV ejection phase indices have reported normal or even hyperdynamic LV function. Even in severe obesity, LV systolic dysfunction is relatively uncommon in the absence of coexisting CVD. In severe obesity, however, the presence of severe LVH causes blunting of the exercise induced rise in LV systolic function. Additionally, studies using tissue Doppler imaging have reported subclinical LV systolic dysfunction in obesity that is thought to be load independent, suggesting the presence of intrinsic abnormalities of LV contraction. 5, 7, 8, 11, 12 More importantly, however, studies demonstrate impaired LV diastolic function in obese patients, especially in combination with LVH. 5, 7, 8 Nevertheless, some studies have reported diastolic LV dysfunction independent of LVM. Although LV diastolic dysfunction has been reported for many years with several imaging techniques, 5, 7, 8, 12, 13 more recent studies with tissue Doppler have particularly identified LV diastolic dysfunction as a subclinical disorder in obesity. The prevalence of LV diastolic dysfunction increases with increases of severity of obesity, from 12% of Class I, 35 % of Class II, and 45 % of Class III obese patients in one study. 14 Most studies demonstrating impaired LV diastolic function in obesity have reported a high prevalence of LVH, with progressive impairment of LV diastolic function with increasing LVM ( presumably due to muscle, fibrosis and intra-myocardial fat.)
Additionally, obesity has adverse affects on the left atrium (LA) and right ventricle (RV), and particularly abnormalities are noted with the common combination of obesity, HTN, and LVH. 
Obesity and HF
Considering the adverse effects of adiposity on hemodynamics and LV structure and ventricular function, not surprisingly, obesity leads to marked increases in the prevalence of HF. 5, 6 Additionally, myocardial lipotoxicity and lipoapoptosis has also been described with severe obesity in animal models and may potentially contribute to an obesity cardiomyopathy in humans; however, other factors, including increased activation of the renin-angiotensin-aldosterone system, increased sympathetic tone, insulin resistance, and hyperleptinemia are likely much more important . 7, 8 Although a detailed discussion of the pathophysiology related with leptin in the development of CVD and HF is beyond the scope of this review and is briefly reviewed elsewhere, 1 leptin is involved with increasing BP and the development of HTN, as well as leading to vascular and myocardial injury, that may be important in the pathogenesis of HF.
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The largest study to assess the risk of HF in obesity is derived from the Framingham Heart
Study. 17 In a study of 5,881 participants, Kenchaiah and colleagues 17 demonstrated a marked increase in the prevalence of HF in both men and women. In fact, for every 1 kg/m 2 increase in BMI, the risk of HF increased by 7% in women and 5% in men, with graded increases in HF prevalence across all BMI categories ( Figure 2 ). 17 Alpert and colleagues 18 have reported that HF is also strongly impacted by obesity severity and duration of obesity. In a study of 74 morbidly obese patients, nearly ⅓ had clinical evidence of HF, and the probability of HF increased substantially with increasing duration of morbid obesity, with prevalence rates exceeding 70% at 20 years and 90% at 30 years.
18
Obesity Paradox in HF
Despite the adverse affects of obesity on LV structure and function that markedly increases the prevalence of HF in obesity, numerous studies have now reported a powerful relationship between obesity and prognosis, with overweight and, especially, obese Class I and II HF patients having the better prognosis than do their leaner counterparts with HF. 5, 6 Horwich and colleagues 19 first described this almost 15 yeas ago, and this association has now been confirmed in many studies and metaanalyses. Sharma and colleagues 20 recently reported a meta-analysis of 6 studies (N=22,807) that assessed adverse events, including CV mortality, all-cause mortality, and rehospitalizations, during a 2.9 year mean follow-up ( Figure 3) ; 20 prognosis was the worst with low BMI, whereas the lowest risk occurred in the overweight Another study of 6,142 patients with acutely decompensated HF from 12
prospective studies from 4 continents also confirmed an obesity paradox, mostly confined to older persons, those with reduced cardiac function, less cardiometabolic illness, and recent onset HF. 
Mechanisms for the Obesity Paradox in HF
The mechanisms for the obesity paradox in CVD and HF particularly remain somewhat unclear and difficult to reconcile, but several potential reasons are listed in Table 2 . 5 Certainly, advanced HF is a catabolic state, and heavier HF patients may have more metabolic reserve, whereas frail and cachectic patients (discussed later) experience greater morbidity and mortality for many diseases, including HF.
Adipose tissue is also known to promote soluble tumor necrosis factor-alpha receptors that could be protective in patients with greater adiposity by neutralizing tumor necrosis factor. Additionally,
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overweight and obese HF patients have reduced expression of circulating natriuretic peptides, 5,26 which could lead obese HF patients to become symptomatic with edema and dyspnea and present earlier with excess volume accumulation occurring at less severe stages of HF, which could lead to earlier treatment with cardioprotective medications. Because obesity is usually associated with greater blood volume and BP, obese patients with HF should be able to tolerate higher doses of various cardioprotective CV medications. Also, although most studies adjust for age, generally the obese HF are slightly younger than the leaner patients, as noted in the 4 year younger age in our recent meta-analysis. 20 As discussed below, adipose tissue in HF may be associated with greater muscular strength, that along with cardiorespiratory fitness (CRF) could also improve HF prognosis.
27,28
Impact of Frailty/Cachexia in HF
Frailty can be defined as a biological syndrome that is characterized by declining overall function and loss of resistance to stressors, which is associated with increased morbidity, mortality, and healthcare expenditures, particularly in the elderly, who have a high prevalence of HF. 28 A recent study indicates that frailty was highly prevalent among community patients with HF, and this predicted a significant increase in the risk of hospitalization and emergency department encounters, independent of other comorbidities. 29 Cachexia is a particularly ominous accompaniment of advanced HF. 28 Certainly, unintentional weight loss carries an extremely high burden of morbidity and mortality for most medical conditions, and the same is true for HF. Although many studies have suggested a worse prognosis associated with weight loss in HF, a limitation of most of these studies is that purposeful weight loss was not differentiated from non-purposeful weight loss, and studies generally were not able to account for non-
A C C E P T E D M A N U S C R I P T
purposeful weight loss prior to study entry. 5, 28 To an extent, overweight and obesity in HF may represent the opposite of cachexia, or reverse epidemiology. 28, 30 Recent studies have suggested that fat loss may precede lean muscle mass loss as cardiac cachexia becomes manifest, and fat loss may signal the onset of declining prognosis in HF. 28, 31 These studies have also made a link between cardiac cachexia and RV dysfunction. Besides preventing weight loss, potentially useful strategies for cardiac cachexia in HF are discussed elsewhere.
28
Impact of Severe or Class III Obesity
Although an obesity paradox exists for most CVD as well as HF, it is most likely that this mostly applies to overweight and mildly obese patients, less so for Class II obesity (BMI 35-40 kg/m . 32, 33 In CHD, for example, although an obesity paradox was noted short-term for all classes of BMI, more severe obesity was associated with worse survival during long-term follow-up. 34, 35 The impact of morbid or Class III obesity in HF prevalence and prognosis is most concerning, since recent studies suggest that more severe obesity is increasing more so than obesity per se. 1, 5 Additionally, this level of severe obesity has particularly detrimental affects on CV structure and function, and, as discussed previously, markedly increases the prevalence of HF. 5, 7, 18 Unlike less severe degrees of obesity, where an obesity paradox generally seems to exist, at least in short-term follow-up studies, many studies suggest that Class III obesity is associated with a poor HF prognosis.
32,33
Impact of Fitness in HF
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Substantial data indicate that muscular strength and levels of CRF markedly impacts prognosis in many CVD patients, including HF. 27, 36 In fact, low levels of CRF may be one of the strongest risk factors for CVD and total mortality. [37] [38] [39] High levels of CRF, including higher workloads on treadmill stress tests, longer 6-minute walking time, and higher peak oxygen consumption (VO 2 ) , are associated with better prognosis in most CVD, including CHD and HF. [36] [37] [38] [39] [40] [41] In addition, Lavie and colleagues 42 demonstrated that CRF strongly mitigates the impact of adiposity on subsequent prognosis in HF. In a study of 2,066 patients with systolic HF, those with a relatively preserved CRF (peak VO 2 ≥ 14 cc/kg/min) have a favorable prognosis regardless of weight. In contrast, those with poor CRF (peak VO 2 < 14 cc/kg/min), a strong obesity paradox was apparent (Figure 4 ), with the lean HF patients, even after excluding underweight patients, with poor CRF having particularly high mortality compared with heavier patients. 42 These data were recently confirmed in a study from Clark et al. 43 These data support physical activity and exercise training to increase levels of CRF to improve prognosis in HF patients. 36 Although the results of the recent HF: ACTION (Heart Failure: A Controlled
Trial Investigating Outcomes of Exercise Training) were less impressive than expected, as the exercise training only produced a modest 4% average increase in peak VO 2 ,(which was well less than the 10% to 15% improvements anticipated), 44 still this therapy reduced the primary endpoint of all-cause mortality in HF hospitalizations by 11% after adjusting for baseline factors. However, in patients who were more compliant with exercise training, greater increases in peak VO 2 were associated with 30% reductions in mortality and hospitalizations. 45 Therefore, recommending exercise training to improve CRF is important to improve HF prognosis. Although randomized controlled trials of resistance training on longterm prognosis are not available in HF, many studies have demonstrated better prognosis associated with higher levels of muscular strength, which are also associated with better quality of life. 27, 28 Thus, it
is reasonable based on current information to include resistance training with aerobic exercise training for most patients with HF.
Intentional Weight Loss in HF
Intentional weight loss may be one of the most effective long-term therapies for improving the hemodynamics and cardiac structure and functional abnormalities associated with obesity, most of which adversely impact HF. 5, 7 Despite this evidence, however, and considering the previously discussed obesity paradox and adverse impact of cardiac cachexia and frailty in HF, 5, 7, 28 Reproduced with permission from Lavie CJ et al.
